A made-in-B.C. prostate cancer drug entering clinical trials

​



​The BC Cancer Foundation is looking for advanced prostate cancer patients that can participate  in a phase one  clinical trial. The Canadian trial will be run by Dr. Kim Chi, who is an Associate Professor at the UBC Division of Medical Oncology.

This is the culmination of 17 years work and over $2.6 million dollars of funding to develop a totally new way of attacking prostate cancer.

A prostate cancer drug developed by researchers at the BC Cancer Agency and the University of British Columbia is entering human clinical trials. The drug is specifically designed to target and shut down metastatic castrate resistant prostate cancer (m-CRPC) when other treatments have failed.
“Today represents a significant milestone as we witness the fruits of our labour in the lab move to the clinic to potentially help men facing metastatic prostate cancer,” said Dr. Marianne Sadar, Distinguished Scientist at the BC Cancer Agency and Professor in the UBC Department of Pathology and Laboratory Medicine. “We faced one in 1000 odds in developing a drug that would prove to be a candidate for patient trials.”
​
Over a decade in the making, the drug EPI-506 is the first to target the ‘back end’ of the androgen receptor protein, called the N-terminal domain. The androgen receptor drives most prostate cancer cells and makes them sensitive to androgen hormones, such as testosterone.


Read More Here

---